Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $52.6 million.

  • Amphastar Pharmaceuticals' Cash from Operations fell 1230.61% to $52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.3 million, marking a year-over-year decrease of 2686.98%. This contributed to the annual value of $213.4 million for FY2024, which is 1628.47% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Cash from Operations stood at $52.6 million for Q3 2025, which was down 1230.61% from $35.6 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cash from Operations peaked at $69.1 million during Q2 2024, and registered a low of $2.6 million during Q3 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Cash from Operations value was $35.6 million (recorded in 2025), while the average stood at $37.2 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Cash from Operations tumbled by 9124.66% in 2022 and then skyrocketed by 185108.35% in 2023.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Cash from Operations stood at $40.4 million in 2021, then crashed by 62.35% to $15.2 million in 2022, then surged by 56.73% to $23.9 million in 2023, then rose by 21.62% to $29.0 million in 2024, then soared by 81.17% to $52.6 million in 2025.
  • Its last three reported values are $52.6 million in Q3 2025, $35.6 million for Q2 2025, and $35.1 million during Q1 2025.